Therapeutic Indications

Lung cancer - other

Microbiome Analysis to Predict Immunotherapy Response

05640

Gut microbiome signatures predict anti-PD-1 therapy response, PFS, and irAEs, guiding personalized cancer immunotherapy.

Technology Type: Diagnostic/Assay
Technology Subtype: Biomarker
Therapeutic Areas: Oncology
Therapeutic Indications: Lung cancer - other
Tags: Clinical Decision Support
Life Science
Lead Inventor: Diwakar Davar
Department: Med-Medicine
All Tech Innovators: Diwakar Davar
Amiran Dzutsev
John McCulloch
Date Submitted: 2021-03-16

uPAR-Targeting Human Antibody for Treating Cancer and Fibrotic Diseases

06240

uPAR-targeting human VH antibodies offer potent, versatile cancer and fibrotic-disease therapy with VH-Fc formats.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - mAb
Therapeutic Areas: Hepatology
Oncology
Therapeutic Indications: Lung cancer - other
Cirrhosis
Melanoma
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Xiaojie Chu
Dimiter Stanchev Dimitrov
Wei Li
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2022-12-06
Collections: Cardiometabolic
Women's & Reproductive Health

Novel KRASG12C Specific Immunotherapy

05494

Triple therapy for KRASG12C cancers: IL-36γ armed OV, covalent KRASG12C inhibitor, and anti-PD-1 boost immunity.

Technology Type: Therapeutic Modality
Technology Subtype: Other Therapeutic Modality
Therapeutic Areas: Oncology
Therapeutic Indications: Lung cancer - other
Pancreatic adenocarcinoma
Colorectal cancer (CRC)
Tags: Life Science
Oncology
Lead Inventor: Zongsheng Guo
Department: Med-Microbiology and Molecular Genetics
All Tech Innovators: Hongqi Chen
Zongsheng Sheng Guo
Binfeng Lu
Date Submitted: 2020-08-26

PDLIM2 Therapy for Cancer

04623

Restoring PDLIM2 enhances antitumor activity, boosts anti-PD-1 therapy, and serves as a cancer biomarker and therapy target.

Technology Type: Therapeutic Modality
Technology Subtype: Drug Discovery - Target
Therapeutic Areas: Oncology
Therapeutic Indications: Lung cancer - other
Lung Cancer - Non-Small Cell
Tags: Drug Repurposing
Lead Inventor: Zhaoxia Qu
Department: Med-Microbiology and Molecular Genetics
All Tech Innovators: Alyssa D. Gregory
Zhaoxia Qu
Steven David Shapiro
Technology Readiness Level: 3. Initial proof of concept, in-vivo
Date Submitted: 2018-05-09

Fully Human Anti-Mesothelin Engineered Antibody VH Domains

05170

Fully human VH-domain CAR-T targets mesothelin tumors; smaller, potentially less immunogenic, improved penetration and cryptic-epitope access.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - scFV
Therapeutic Areas: Oncology
Therapeutic Indications: Lung cancer - other
Pancreatic adenocarcinoma
Ovarian cancer
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Dimiter Stanchev Dimitrov
John W. Mellors
Zehua Sun
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2019-11-15
Collections: Women's & Reproductive Health

MultiPlex Sensors for Increasing Information Content and Performance of Electronic Noses

06104

Pressure-tunable MOF-based electronic noses boost information content and cross-sensitivity with a single compressor.

Technology Type: Engineering Technology
Technology Subtype: Sensor
Therapeutic Areas: Oncology
Therapeutic Indications: Lung cancer - other
Tags: Diagnostic Imaging
Oncology
Sensor
Lead Inventor: Brian Day
Department: Chem/Petroleum Engineering
All Tech Innovators: Brian Austin Day
Christopher Eli Wilmer
Date Submitted: 2022-07-18

Novel Human Antibodies Targeting ENPP1

05859

Novel fully human anti-ENPP1 antibodies offer targeted cancer immunotherapy potential, compatible with BiTE, CAR-T, and ADC strategies.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - mAb
Therapeutic Areas: Immunology
Oncology
Therapeutic Indications: Lung cancer - other
Ductal carcinoma (Breast cancer)
Solid tumor
Tags: Immuno-oncology
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Dusan Baek
Xiaojie Chu
Dimiter Stanchev Dimitrov
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2021-10-30
Collections: Women's & Reproductive Health

Fully Human FAbs to IGF-1 and IGF-2

04929

Fully human IGF-1/IGF-2–binding Fabs block IGF signaling to curb cancer cell growth, offering novel therapeutics.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - Fab
Therapeutic Areas: Oncology
Therapeutic Indications: Lung cancer - other
Prostate cancer / adenocarcinoma
Ductal carcinoma (Breast cancer)
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Dusan Baek
Dimiter Stanchev Dimitrov
John W. Mellors
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2019-03-24
Collections: Women's & Reproductive Health

Human Antibody Domains and Fragments to CD276

06094

engineered fully human single-domain antibodies and Fabs targeting CD276 (B7-H3) for potent, broadly applicable cancer immunotherapy.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - mAb
Therapeutic Areas: Oncology
Therapeutic Indications: Lung cancer - other
Melanoma
Prostate cancer / adenocarcinoma
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Dimiter Stanchev Dimitrov
Dontcho V. Jelev
John W. Mellors
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2022-07-06

Antibody Domains that bind to Neutrophil Elastase (NE) polypeptides

05643

Antibody domains targeting neutrophil elastase inhibit its activity, offering cancer and inflammatory disease therapy with ADC potential.

Technology Type: Therapeutic Modality
Technology Subtype: Antibody - mAb
Therapeutic Areas: Oncology
Therapeutic Indications: Lung cancer - other
Ductal carcinoma (Breast cancer)
Lead Inventor: Dimiter Dimitrov
All Tech Innovators: Dusan Baek
Xiaojie Chu
Dimiter Stanchev Dimitrov
Technology Readiness Level: 2. Initial proof of concept, in-vitro
Date Submitted: 2021-03-17
Collections: Women's & Reproductive Health

Gastrin-Releasing Peptide Receptor Transgenic Mouse

01176

Generated GRPR-overexpressing mice in airway epithelium reveal altered bronchiolar structure, suggesting GRPR’s role in lung tumorigenesis.

Technology Type: Life Science Research Tool
Technology Subtype: Animal Model
Therapeutic Areas: Oncology
Therapeutic Indications: Lung cancer - other
Lung Cancer - Non-Small Cell
Lead Inventor: Jill Siegfried
Department: Med-Pharmacology and Chemical Biology
All Tech Innovators: Xuwan Liu
Jill M. Siegfried Ph.D.
Laura Ann Stabile
Date Submitted: 2005-11-18

Hepatocyte Growth Factor Transgenic Mouse

01177

Transgenic mice overexpressing HGF in lungs accelerate tobacco-induced lung tumorigenesis, modeling aggressive HGF/c-Met–driven adenocarcinoma.

Technology Type: Life Science Research Tool
Technology Subtype: Animal Model
Therapeutic Areas: Oncology
Therapeutic Indications: Lung cancer - other
Lung Cancer - Non-Small Cell
Lead Inventor: Jill Siegfried
Department: Med-Pharmacology and Chemical Biology
All Tech Innovators: Jill M. Siegfried Ph.D.
Laura Ann Stabile
Date Submitted: 2005-11-18

Novel Method for Safer Lung Cancer Screening

06213

Personalized LDCT risk tool tailors lung cancer screening, reducing unnecessary tests and targeting high-risk patients.

Technology Type: Medical Device
Technology Subtype: Diagnostic Imaging
Therapeutic Areas: Oncology
Therapeutic Indications: Lung cancer - other
Lung Cancer - Non-Small Cell
Lead Inventor: Jiantao Pu
Department: Med-Radiology
All Tech Innovators: Jiantao Pu
Date Submitted: 2022-11-11

DNA Variants in Personalized Cancer Therapy

03411

Personalized cancer therapy via PARP1 gene variants predicts chemo sensitivity/resistance, guiding PARP inhibitor use across cancers.

Technology Type: Diagnostic/Assay
Technology Subtype: Biomarker
Therapeutic Areas: Oncology
Therapeutic Indications: Lung cancer - other
Ductal carcinoma (Breast cancer)
Lead Inventor: Hussein Tawbi
Department: Med-Medicine
All Tech Innovators: Irina Abecassis
Panagiotis Benos
Petr Pancoska
Date Submitted: 2014-09-23
Collections: Women's & Reproductive Health